ARCHIVES

Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

NCI To Ask HCFA to Launch Pilot Clinical Trials Program

March 22, 1996

In Brief: ASCO Congratulates Klausner; UCLA Names Gasson Head Of Jonsson Center

August 4, 1995

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

Tamoxifen Listed By IARC Report As Carcinogen CTRF Seeks Applicants

March 1, 1996

NCAB Committee Reaches Consensus On Organ Systems; DeVita Goes Along

February 4, 1983

Memorial Sloan Kettering Seizes Top Cancer Hospital Prize From MD Anderson In U.S. News & World Report Ranking

July 18, 2014